Stay updated on Efgartigimod in Post-COVID-19 POTS Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.

Latest updates to the Efgartigimod in Post-COVID-19 POTS Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision: v3.4.2 was added to the page. The previous items, including a government-funding operating-status notice and Revision: v3.4.1, were removed.SummaryDifference0.4%

- Check30 days agoChange DetectedAdded a government funding notice and updated the site revision to v3.4.1; these are general page-wide updates and do not alter study details or eligibility criteria.SummaryDifference0.4%

- Check37 days agoChange DetectedThe page now includes a Show glossary option and updated metadata: Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check51 days agoChange DetectedAdministrative revision notes updated from v3.3.3 to v3.3.4, with no changes to study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check72 days agoChange DetectedAdded a Locations section listing California, Illinois, Maryland, Massachusetts, Ohio, Tennessee, Texas, and Utah, and updated the page version to v3.3.3. Removed the prior location sections for those states and the HHS Vulnerability Disclosure, corresponding to the v3.3.2 changes.SummaryDifference0.9%

- Check101 days agoChange DetectedThe Publications section text was updated to clarify PubMed as the source for publications. The page revision number was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Efgartigimod in Post-COVID-19 POTS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.